Because MUC1 and HER2 are, in composite, hyperexpressed by the majority of human cancers [38, 92], the ability to readily grow out natural T1-type CD4+ and CD8+ T-cells recognizing these Ags, even from the PBMC of non-vaccinated donors, has the potential to make adoptive natural T-cell therapy applicable to most cancer patients, also potentially bypassing the need for vaccine maneuvers which themselves could prematurely result in tumor escape through immunoediting [38]. Here, ERBB2 is linked to neoplasm.